R.p.scherer Technologies, Inc.

Merck Sharp + Dohme Corp.

Prothena Biosciences Limited

Teijin Pharma Limited

Other

Merck Sharp & Dohme LLC

Jeanne E Baker

David Rabuka

Gregory W deHart

Patrick Holder

Theodore A Yednock

Kenneth Flanagan

Carl Mieczkowski

Sophie Parmentier Batteur

Takashi Murakami

Hiroshi H Eguchi

Akira Tanokura

Naoko Namiki

Angela Marie Jablonski

Daniel Stephen Malashock

Gopalan (Raghu) Raghunathan

Chung-Ming Hsieh

Alan C Cheng

Gopalan Raghunathan

Ming-Tang Chen

Sokreine Suon

The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.

Activated formylglycine-generating enzymes and methods of producing and using the same

The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.

Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

High affinity antibodies targeting tau phosphorylated at serine 413

Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin &#x3b1;-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

Anti-MCAM antibodies and associated methods of use

Growing community of inventors

Redwood City, CA, United States of America

Jeanne E Baker